NCT00096200 2022-02-08
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
11 trialsNCT00436215 2020-11-23
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00093626 2019-07-23
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00522301 2016-02-29
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00238121 2015-11-20
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00791778 2015-09-28
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Bayer
Phase 2 Completed
NCT00510250 2015-07-27
A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT01047891 2015-02-18
TRIAS 2009
Charite University, Berlin, Germany
Phase 2 Completed
NCT00390611 2014-12-22
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00096395 2013-06-13
Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed